NovoCure Limited
NVCR
$17.24
$0.392.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 174.06M | 174.35M | 167.20M | 158.81M | 154.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 174.06M | 174.35M | 167.20M | 158.81M | 154.99M |
| Cost of Revenue | 38.93M | 40.45M | 44.73M | 41.47M | 38.52M |
| Gross Profit | 135.13M | 133.90M | 122.48M | 117.33M | 116.47M |
| SG&A Expenses | 144.21M | 110.18M | 104.47M | 101.02M | 98.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 241.48M | 211.53M | 203.23M | 198.33M | 190.56M |
| Operating Income | -67.42M | -37.18M | -36.02M | -39.52M | -35.57M |
| Income Before Tax | -69.26M | -40.95M | -30.02M | -34.98M | -30.30M |
| Income Tax Expenses | 1.88M | -16.46M | 7.25M | 5.16M | 4.02M |
| Earnings from Continuing Operations | -71.14M | -24.50M | -37.27M | -40.14M | -34.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.14M | -24.50M | -37.27M | -40.14M | -34.32M |
| EBIT | -67.42M | -37.18M | -36.02M | -39.52M | -35.57M |
| EBITDA | -63.30M | -34.48M | -32.36M | -36.08M | -32.24M |
| EPS Basic | -0.62 | -0.22 | -0.33 | -0.36 | -0.31 |
| Normalized Basic EPS | -0.38 | -0.36 | -0.17 | -0.20 | -0.16 |
| EPS Diluted | -0.62 | -0.22 | -0.33 | -0.36 | -0.31 |
| Normalized Diluted EPS | -0.38 | -0.36 | -0.17 | -0.20 | -0.16 |
| Average Basic Shares Outstanding | 114.15M | 112.24M | 111.91M | 111.57M | 110.28M |
| Average Diluted Shares Outstanding | 114.15M | 112.24M | 111.91M | 111.57M | 110.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |